Erlotinib Completed Phase 2 Trials for Adenocarcinoma, Bronchiolo-Alveolar Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00384826Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma